ScholarX: KOO, DONG HOE

Detailed Information

KOO, DONG HOE (구동회)

Medicine (Medicine)

Research Area

Tel 02-2001-8330
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Chemotherapy:7||Gastric cancer:5||Prognosis:5||Stomach neoplasms:4||2:4||gastric cancer:3||radiofrequency ablation:2||1700:2||Progranulin:2||mortality:2||Advanced gastric cancer:2||Paclitaxel:2||Colorectal neoplasms:2||Neoplasms:2||Pancreatic neoplasms:2||Trastuzumab:2||Treatment outcome:2||Nivolumab:2||Anemia:1||Antiemetics:1||Aprepitant:1||Asia:1||Attitude:1||Bcl6:1||Biliary tract cancer:1||Biomarker enriched:1||Breakthrough pain:1||Breast neoplasms:1||CD10:1||CHEMOTHERAPY:1||CHOP chemotherapy:1||Cancer chemotherapy:1||Carboplatin:1||Child–Pugh classification:1||Chronic myeloid leukemia:1||Clinical trials:1||Complication:1||Country adaptation:1||Cumulative glucose levels:1||Cytogenetic Analysis:1||DNA methylation:1||Dexamethasone:1||Diabetes mellitus:1||Diffuse large Bcell lymphoma (DLBCL):1||Docetaxel:1||Dosing:1||Drug Therapy:1||EGFR tyrosine kinase inhibitor:1||Education:1||Elderly:1||Emesis:1||Endoscopy:1||Epidermal growth factor receptor:1||Epigenomics:1||Ethanol:1||Etoposide:1||Expanded access program:1||Fentanyl:1||Field effect:1||Firstline:1||Firstline palliative chemotherapy:1||Fluorouracil:1||Gastrointestinal stromal tumors:1||Germinal center Bcell (GCB):1||Guideline:1||HER2:1||Hans&apos:1||Hiccup:1||Hyperglycemic burden:1||Ifosfamide:1||Imatinib mesylate:1||Immune checkpoint inhibitors:1||Incidence:1||Irinotecan:1||Key words Chemotherapy:1||Korea:1||Lymphatic invasion:1||Malignant lymphoma:1||Malignant pleural effusion:1||Metastasis:1||Metastatic:1||Methylprednisolone:1||Multidisciplinary:1||Multiple myeloma:1||National Health Insurance:1||National health insurance:1||Nausea:1||Nongerminal center Bcell (NonGCB):1||Nonsmall cell lung carcinoma:1||Older adults:1||Oncology:1||Opioid:1||PTEN:1||Palonosetron:1||PatientCentered Care:1||Pembrolizumab:1||Peritumor administration:1||Perineural invasion:1||Period:1||Pleurodesis:1||Predictive:1||Professional practice:1||Protocols & guidelines:1||Publication:1||Publication bias:1||Quality of life:1||Ramosetron:1||Ramucirumab:1||Randomized Controlled Trial:1||Recurrence:1||Regorafenib:1||Reimbursement:1||Reporting:1||Resistance:1||Response:1||Resuscitation orders:1||Risk:1||Secondline chemotherapy:1||Sex:1||Small cell lung cancer:1||Sodium caprate:1||Stomach Neoplasms:1||Stomach neoplasm:1||Sunitinib:1||Surgery:1||Tau:1||Thirdline treatment:1||Thrombospondin 1:1||Treatment timing:1||Trial registration:1||Tuberculosis:1||USP10:1||Validation:1||Value frameworks:1||Varlitinib:1||Vascular endothelial growth factor:1||Venous invasion:1||Viscum album:1||Vomiting:1||albumin–bilirubin grade:1||algorithm:1||apoptosis:1||breast cancer:1||buprenorphine:1||cancer survivors:1||chemotherapy:1||cohort study:1||colorectal cancer:1||colorectal neoplasms:1||conebeam computed tomography:1||eHealth:1||gastroesophageal junction cancer:1||gastrointestinal tumours:1||guidelines:1||hepatocellular carcinoma:1||hollow microneedle:1||imatinib cessation:1||local tumor control:1||longterm followup:1||lung cancer:1||lung metastases:1||lung neoplasms:1||methylation:1||necrosis:1||neutrophiltolymphocyte ratio:1||opioidrelated disorders:1||p14ARF:1||pembrolizumab:1||prescription drugs:1||prognosis:1||prognostic factor:1||programmed death 1:1||progranulin:1||protocols &:1||qualityoflife:1||radiotherapy:1||solgel formulation:1||substance withdrawal syndrome:1||surgery:1||transarterial chemoembolization:1||virtual navigation guidance:1||xenograft:1||경험:1||교육:1||심폐소생술금지:1||1:1||태도:1||130540543122772683:1||1589:1||239:1||2614921992823:1||261492353223705109:1||2813189499:1||283237255:1||3:1||3282330646143760:1||4:1||5:1||5FU:1||6:1||8:1||Advanced breast cancer:1||Agegroups:1||Analgesics:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE